These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 17605185)
21. The proliferation of irrational metformin fixed-dose combinations in India. Evans V; Pollock AM Lancet Diabetes Endocrinol; 2015 Feb; 3(2):98-100. PubMed ID: 25618292 [No Abstract] [Full Text] [Related]
22. [Metformin in serum. Results of a study as basis for preliminary therapeutic recommendations]. Frid A; Sterner G; Löndahl M; Vinge E; Cato A; Andersson A Lakartidningen; 2009 Feb 11-17; 106(7):428-9. PubMed ID: 19350768 [No Abstract] [Full Text] [Related]
23. New treatment for diabetes. FDA Consum; 2007; 41(1):3. PubMed ID: 17342826 [No Abstract] [Full Text] [Related]
24. [Metformin should not be used by patients with reduced renal function]. Gudmundsdottir H; Brørs O; Os I Tidsskr Nor Laegeforen; 2008 Apr; 128(8):936-7. PubMed ID: 18431417 [No Abstract] [Full Text] [Related]
25. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable. Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232 [TBL] [Abstract][Full Text] [Related]
26. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Raskin P Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804 [TBL] [Abstract][Full Text] [Related]
28. Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes. Gottschalk M; Danne T; Fuerst-Recktenwald S Pediatr Diabetes; 2009 Jun; 10(4):240-7. PubMed ID: 19493247 [No Abstract] [Full Text] [Related]
29. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007 [TBL] [Abstract][Full Text] [Related]
34. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Schwartz SL; Gordi T; Hou E; Cramer M; Heritier M; Cowles VE Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1235-43. PubMed ID: 18721117 [TBL] [Abstract][Full Text] [Related]
35. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE J Clin Pharmacol; 2008 Jun; 48(6):696-707. PubMed ID: 18372428 [TBL] [Abstract][Full Text] [Related]
36. Metformin as firstline treatment for type 2 diabetes: are we sure? Boussageon R; Gueyffier F; Cornu C BMJ; 2016 Jan; 352():h6748. PubMed ID: 26747716 [TBL] [Abstract][Full Text] [Related]
38. DPP-4 inhibitors. A new class of drugs for type 2 diabetes. Marino MT Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028 [No Abstract] [Full Text] [Related]
39. Pioglitazone + metformin: new drug. A combination product to avoid. Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17724835 [TBL] [Abstract][Full Text] [Related]
40. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]